Biohaven Pharmaceutical Holding Company

World Rank (Jan-05-2024)

3,972

Market Cap (Jan-05-2024)

3.399 Billion USD

World Rank (Jul-30-2023)

7,470

Market Cap (Jul-30-2023)

1.300 Billion USD

World Rank (Jan-07-2022)

2,147

Market Cap (Jan-07-2022)

8.441 Billion USD

World Rank (Jan-01-2021)

2,858

Market Cap (Jan-01-2021)

5.137 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

BHVN

Market Cap (Mar-08-2026)

1.49

Employee Count

797

Employee Count as of Date

As on 2021

Headquarters City/State

Connecticut

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

0 Million USD

Annual Operating Income in USD

-567 Million USD

Annual Net Income in USD

-570 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

661 Million USD

Total Liabilities in USD

123 Million USD

Total Equity in USD

538 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Yahoo

Yahoo @ NYSE

Company Profile

Biohaven Pharmaceutical Holding Company is a Clinical Stage Biopharmaceutical company. It portfolio is comprised of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases including rare disorders. The company is rapidly progressing multiple compounds in clinical trials across three platforms they are calcitonin gene related peptide receptor antagonism, glutamate modulation and myeloperoxidase inhibition. The headquarters is in USA.

Annual Results Summary

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - Yearly Revenue and Net Income - in Million USD:

Year - Ending	Revenue	Gross Profit	Operating Income	Net Income
Dec-2021	462	370	-704 (Loss)	-846 (Loss)
Dec-2020	63	45	-645 (Loss)	-766 (Loss)
Dec-2019	0	-	-479 (Loss)	-528 (Loss)
Dec-2018	0	-	-224 (Loss)	-240 (Loss)